Evonik Industries AG (Essen, Germany) is making a significant investment to strengthen manufacturing capabilities at its ...
Recently, innovative pharmaceutical company BeiGene disclosed a substantial tax back payment matter, with the company required to pay a total of 446 million yuan in back taxes. The announcement ...
U.S. Market Projected to Expand USD 0.76 Billion by 2035, While Europe Advances Toward USD 0.51 Billion on EU Antibiotic Ban ...
As enterprises increasingly demand fail-safes against single-vendor reliance, Sakana is proving that packaging collective intelligence into a single API endpoint is a highly viable commercial path.
TLDR: ANDES reframes data synthesis for autonomous post-training as an interactive agent skill. A trainer agent decomposes downstream benchmarks into capability domains, invokes ANDES once per domain, ...
Fusion uses multiple AI models together to improve output quality at lower cost. OpenRouter debuts Fusion, a multi-model composite AI Fusion outperforms single models, scoring 69% on DRACO benchmark ...
Anthropic’s Fable and Mythos models have been withdrawn following US export controls, but OpenRouter might have a solution. The company has launched Fusion, a compound model API that fans a prompt out ...
What if instead of picking the smartest person in the room, you could ask five of them and synthesize the best answer? That’s essentially what OpenRouter is betting on with Fusion, a new API feature ...
On June 2, 2026, Microsoft announced seven of its proprietary AI models, including the inference model ' MAI-Thinking-1 ' and the compact coding model ' MAI-Code-1-Flash. ' Of the announced models, ...
Chemists are under pressure to evaluate more ideas, faster, without sacrificing synthetic realism. With vast libraries to choose from, and limited time, software that can free-up resources for ...
This is the Speech Dispatcher project (speech-dispatcher). It is a part of the Free(b)soft project, which is intended to allow blind and visually impaired people to work with computer and Internet ...
AbbVie’s $100 billion splurge on domestic manufacturing and R&D is continuing to come into focus, this time with a $380 million investment in two new active pharmaceutical ingredient manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results